---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-23-000020"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T16:57:39.014245+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SELLAS reports Q2 net loss $8.8M; AML trials on track with IDMC meeting Q3 2023

## Summary
- Net loss $8.8M ($0.31/share) vs $8.4M ($0.41/share) in Q2 2022; cash $13.8M at June 30.
- Phase 3 REGAL (GPS) interim analysis expected late 2023/early 2024; IDMC meeting in Q3 2023.
- Phase 2a SLS009 in AML dosed; topline data expected Q4 2023; Phase 1 safety completed.
- Expects $13M milestone payments from 3D Medicines by end of Q3 2023.
- R&D expenses $5.9M (up from $5.5M) driven by GPS and SLS009 trials.

## SEC filing metadata
- accession: 0001390478-23-000020
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/0001390478-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/sls-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-23-000020
- JSON: https://secwatch.observer/filing/0001390478-23-000020.json
- Plain text: https://secwatch.observer/filing/0001390478-23-000020.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/0001390478-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.